Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Eastern Cooperative Oncology Group
University of California, San Diego
Emory University
NRG Oncology
Mayo Clinic
Cedars-Sinai Medical Center
University of Kentucky
University of California, San Diego
Regeneron Pharmaceuticals
University of Utah
University of California, San Francisco
Eastern Cooperative Oncology Group
Incyte Corporation
Amgen
Mirror Biologics, Inc.
University of Chicago
Eli Lilly and Company
University of Chicago
Sanofi
Oncolytics Biotech
University of Michigan Rogel Cancer Center
Memorial Sloan Kettering Cancer Center
Pfizer